Arena Pharmaceuticals Inc (ARNA)-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:Arena Pharmaceuticals Inc (ARNA) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8014343
◆発行会社(調査会社):GlobalData
◆発行日:2017年11月22日
◆ページ数:61
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Arena Pharmaceuticals Inc (Arena) is a biopharmaceutical company which discovers, develops and commercializes small molecule drugs in multiple therapy areas. Its pipeline portfolio encompasses etrasimod for multiple inflammatory indications; ralinepag for the treatment of pulmonary arterial hypertension (PAH); and APD371 for pain associated with Crohn’s disease. The company also has partnered development programs including Belviq (lorcaserin HCl) for chronic weight management for adults with obesity; nelotanserin for patients with Lewy body dementia (LBD) suffering from visual hallucinations. The company has collaborations with Eisai, Axovant Sciences and Boehringer Ingelheim. It has a manufacturing facility in Zofingen, Switzerland. Arena is headquartered in San Diego, California, the US.

Arena Pharmaceuticals Inc (ARNA) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Arena Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Arena Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Arena Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Arena Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
Arena Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Arena Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 12
Partnerships 12
Boehringer Ingelheim Enters into Research Agreement with Arena Pharma 12
Arena Pharma Enters into Co-Development and Marketing Agreement with Roivant 13
Abic Marketing Enters into Agreement with Arena Pharma 14
Eisai Amends its Co-Marketing Agreement with Arena Pharma for Belviq 15
Arena Pharma Enters Into Co-Marketing Agreement With CY Biotech For Lorcaserin 17
Arena Pharma Enters Into Co-Marketing Agreement With Ildong Pharma For Belviq 18
Arena Pharma Expands Co-Marketing Agreement With Eisai For Lorcaserin 19
Licensing Agreements 20
Arena Pharma Enters Into Licensing And Co-Development Agreement With Ildong Pharma For Temanogrel 20
Suzhou Connect Biopharma Enters Into Licensing Agreement With Arena Pharma For Inflammatory Compounds 22
Equity Offering 23
Arena Pharma Raises USD172.5 Million in Public Offering of Shares 23
Arena Pharma Raises USD79.4 Million in Public Offering of Shares 25
Arena Pharma to Raise Funds through Public Offering of Shares 27
Arena Pharma Completes Public Offering Of Common Stock For US$70 Million 28
Arena Pharma Completes Private Placement Of Common Stock For US$16.5 Million 29
Arena Pharma Completes Private Placement Of Series D Preferred Stock For US$16.5 Million 31
Arena Pharma Announces Private Placement Of Common Stock For US$50 Million 33
Arena Pharma Completes Registered Direct Offering Of Common Stock For US$18 Million 34
Arena Pharma Completes Registered Direct Offering Of Series C Preferred Stock For US$18 Million 36
Arena Pharmaceuticals Inc – Key Competitors 38
Arena Pharmaceuticals Inc – Key Employees 39
Arena Pharmaceuticals Inc – Locations And Subsidiaries 40
Head Office 40
Other Locations & Subsidiaries 40
Recent Developments 41
Strategy And Business Planning 41
Sep 01, 2016: Arena Pharmaceutics Announces Formation of Beacon Discovery 41
Financial Announcements 42
Nov 07, 2017: Arena Pharmaceuticals Provides Corporate Update and Reports Third Quarter 2017 Financial Results 42
Aug 07, 2017: Arena Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2017 Financial Results 43
May 09, 2017: Arena Pharmaceuticals Provides Corporate Update and Reports First Quarter 2017 Financial Results 45
Mar 14, 2017: Arena Pharmaceuticals Provides Corporate Update and Reports Fourth Quarter and Full-Year 2016 Financial Results 46
Nov 07, 2016: Arena Pharmaceuticals Reports Third Quarter 2016 Financial Results and Provides Corporate Update 48
Aug 08, 2016: Arena Pharmaceuticals Reports Second Quarter 2016 Financial Results and Provides Corporate Update 49
May 09, 2016: Arena Pharmaceuticals Reports First Quarter 2016 Financial Results and Provides Corporate Update 50
Feb 29, 2016: Arena Pharmaceuticals Reports Fourth Quarter and Full Year 2015 Financial Results and Provides Corporate Update 51
Corporate Communications 53
Jun 14, 2017: Arena Pharmaceuticals Appoints Jennifer Jarrett to Board of Directors 53
Mar 20, 2017: Arena Pharmaceuticals Appoints Dr. Preston Klassen, M.D., M.H.S. as Executive Vice President, Research and Development and Chief Medical Officer 54
Feb 14, 2017: Arena Pharmaceuticals Appoints Three New Members to Board of Directors 55
Jun 15, 2016: Arena Pharmaceuticals Announces Appointment of Kevin R. Lind as Chief Financial Officer 56
May 09, 2016: Arena Pharmaceuticals Announces Appointment of Amit D. Munshi as President and Chief Executive Officer 57
Product News 58
10/11/2016: Arena Pharmaceuticals Announces Acceptance of Late Breaking Etrasimod Abstract at the United European Gastroenterology Week (UEGW) Meeting 58
06/13/2016: Arena Pharmaceuticals Announces USAN Approval of Nonproprietary Name “Etrasimod” for its Drug Candidate APD334 59
Other Significant Developments 60
Jun 30, 2016: Arena Pharmaceuticals Announces Shift to Focus on Proprietary Clinical Stage Pipeline 60
Appendix 61
Methodology 61
About GlobalData 61
Contact Us 61
Disclaimer 61

List of Tables
Arena Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2016 2
Arena Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Arena Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Arena Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Arena Pharmaceuticals Inc, Deals By Therapy Area, 2011 to YTD 2017 9
Arena Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Boehringer Ingelheim Enters into Research Agreement with Arena Pharma 12
Arena Pharma Enters into Co-Development and Marketing Agreement with Roivant 13
Abic Marketing Enters into Agreement with Arena Pharma 14
Eisai Amends its Co-Marketing Agreement with Arena Pharma for Belviq 15
Arena Pharma Enters Into Co-Marketing Agreement With CY Biotech For Lorcaserin 17
Arena Pharma Enters Into Co-Marketing Agreement With Ildong Pharma For Belviq 18
Arena Pharma Expands Co-Marketing Agreement With Eisai For Lorcaserin 19
Arena Pharma Enters Into Licensing And Co-Development Agreement With Ildong Pharma For Temanogrel 20
Suzhou Connect Biopharma Enters Into Licensing Agreement With Arena Pharma For Inflammatory Compounds 22
Arena Pharma Raises USD172.5 Million in Public Offering of Shares 23
Arena Pharma Raises USD79.4 Million in Public Offering of Shares 25
Arena Pharma to Raise Funds through Public Offering of Shares 27
Arena Pharma Completes Public Offering Of Common Stock For US$70 Million 28
Arena Pharma Completes Private Placement Of Common Stock For US$16.5 Million 29
Arena Pharma Completes Private Placement Of Series D Preferred Stock For US$16.5 Million 31
Arena Pharma Announces Private Placement Of Common Stock For US$50 Million 33
Arena Pharma Completes Registered Direct Offering Of Common Stock For US$18 Million 34
Arena Pharma Completes Registered Direct Offering Of Series C Preferred Stock For US$18 Million 36
Arena Pharmaceuticals Inc, Key Competitors 38
Arena Pharmaceuticals Inc, Key Employees 39
Arena Pharmaceuticals Inc, Other Locations 40
Arena Pharmaceuticals Inc, Subsidiaries 40

★海外企業調査レポート[Arena Pharmaceuticals Inc (ARNA)-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Midea Group Co Ltd:企業の戦略・SWOT・財務分析
    Midea Group Co Ltd - Strategy, SWOT and Corporate Finance Report Summary Midea Group Co Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Fortis Inc (FTS):電力:M&Aディール及び事業提携情報
    Summary Fortis Inc (Fortis) is an oil and gas company that provides development of assets and market capitalization programs. The company offers measurement and monitoring of environmental impacts. It also provides capital program and growth plans to meet the energy needs. Fortis support and partici …
  • Taiwan Shin Kong Commercial Bank Co., Ltd.:企業の戦略・SWOT・財務情報
    Taiwan Shin Kong Commercial Bank Co., Ltd. - Strategy, SWOT and Corporate Finance Report Summary Taiwan Shin Kong Commercial Bank Co., Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, …
  • ITT Inc.:企業のM&A・事業提携・投資動向
    ITT Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's ITT Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capital …
  • Fuji Oil Co Ltd (5017):企業の財務・戦略的SWOT分析
    Fuji Oil Co Ltd (5017) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses an …
  • PT Dian Swastatika Sentosa Tbk (DSSA):企業の財務・戦略的SWOT分析
    PT Dian Swastatika Sentosa Tbk (DSSA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths an …
  • Passenger Rail Agency of South Africa:企業の戦略的SWOT分析
    Passenger Rail Agency of South Africa - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and maj …
  • Enercon GmbH:企業の戦略的SWOT分析
    Enercon GmbH - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. …
  • Permian Basin Royalty Trust Oil & Gas Exploration and Production Operations and Cost Analysis – Q4, 2017
    Permian Basin Royalty Trust Oil & Gas Exploration and Production Operations and Cost Analysis - Q4, 2017 Summary Permian Basin Royalty Trust (Permian Basin Royalty) is an oil and gas company that owns overriding royalty rights in mineral properties in the US. The company provides oil and gas product …
  • Volkswind GmbH:企業の戦略的SWOT分析
    Volkswind GmbH - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and service …
  • Emirates Flight Catering:企業の戦略・SWOT・財務分析
    Emirates Flight Catering - Strategy, SWOT and Corporate Finance Report Summary Emirates Flight Catering - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • Huron Consulting Group Inc:企業のM&A・事業提携・投資動向
    Huron Consulting Group Inc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Huron Consulting Group Inc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acqui …
  • Sinolink Worldwide Holdings Ltd:企業の戦略・SWOT・財務情報
    Sinolink Worldwide Holdings Ltd - Strategy, SWOT and Corporate Finance Report Summary Sinolink Worldwide Holdings Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product …
  • Alchemia Ltd (ACL):製薬・医療:M&Aディール及び事業提携情報
    Summary Alchemia Ltd (Alchemia) is an early stage biopharmaceutical company that focuses on the discovery and development of drugs for the treatment of various diseases. It sold the worldwide exclusive intellectual property rights to its product, Fondaparinux sodium (a generic version of the anticoa …
  • Mateon Therapeutics Inc (MATN):企業の財務・戦略的SWOT分析
    Summary Mateon Therapeutics Inc (Mateon), formerly OXiGENE Inc is a biopharmaceutical company developing investigational drugs for the treatment of orphan oncology indications. The company develops therapeutics to treat cancer and eye diseases; and anti-vascular drugs such as vascular disrupting age …
  • British Polythene Industries Plc:企業の戦略・SWOT・財務分析
    British Polythene Industries Plc - Strategy, SWOT and Corporate Finance Report Summary British Polythene Industries Plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, produ …
  • Eskom Holdings SOC Ltd:電力:M&Aディール及び事業提携情報
    Summary Eskom Holdings SOC Ltd (Eskom) is a state-owned power utility that generates, transmits and distributes electricity. It generates electricity from coal-fired, gas-fired, hydro and pumped storage power plants, and nuclear power plants, among others. The company supplies electricity to industr …
  • Campine NV (CAMB):企業の財務・戦略的SWOT分析
    Campine NV (CAMB) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Nihon Chouzai Co Ltd (3341):企業の財務・戦略的SWOT分析
    Nihon Chouzai Co Ltd (3341) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakness …
  • Advanced Data Systems Corp-医療機器分野:企業M&A・提携分析
    Summary Advanced Data Systems Corp (ADS) is a healthcare technology company that develops medical billing and office automation software tools. The company offers electronic health records, practice management solution, radiology information systems solutions, revenue cycle management services and b …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆